studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), sintillimab plus SoC vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsORIENT-11, 2020 0.61 [0.40; 0.93] 0.61[0.40; 0.93]ORIENT-11, 202010%397NAnot evaluable progression or deaths (PFS)detailed resultsORIENT-11, 2020 0.48 [0.36; 0.64] 0.48[0.36; 0.64]ORIENT-11, 202010%397NAnot evaluable objective responses (ORR)detailed resultsORIENT-11, 2020 2.54 [1.63; 3.97] 2.54[1.63; 3.97]ORIENT-11, 202010%397NAnot evaluable AE (any grade)detailed resultsORIENT-11, 2020 1.02 [0.03; 30.46] 1.02[0.03; 30.46]ORIENT-11, 202010%397NAnot evaluable AE (grade 3-4)detailed resultsORIENT-11, 2020 1.13 [0.74; 1.73] 1.13[0.74; 1.73]ORIENT-11, 202010%397NAnot evaluable AE leading to death (grade 5)detailed resultsORIENT-11, 2020 0.31 [0.11; 0.90] 0.31[0.11; 0.90]ORIENT-11, 202010%397NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsORIENT-11, 2020 0.70 [0.31; 1.55] 0.70[0.31; 1.55]ORIENT-11, 202010%397NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsORIENT-11, 2020 0.64 [0.26; 1.56] 0.64[0.26; 1.56]ORIENT-11, 202010%397NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.49 [0.01; 24.91] 0.49[0.01; 24.91]ORIENT-11, 202010%397NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.49 [0.01; 24.91] 0.49[0.01; 24.91]ORIENT-11, 202010%397NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.49 [0.01; 24.91] 0.49[0.01; 24.91]ORIENT-11, 202010%397NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.49 [0.01; 24.91] 0.49[0.01; 24.91]ORIENT-11, 202010%397NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.49 [0.01; 24.91] 0.49[0.01; 24.91]ORIENT-11, 202010%397NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.98 [0.09; 10.96] 0.98[0.09; 10.96]ORIENT-11, 202010%397NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.49 [0.01; 24.91] 0.49[0.01; 24.91]ORIENT-11, 202010%397NAnot evaluable Rash TRAE (grade 3-4)detailed resultsORIENT-11, 2020 0.16 [0.02; 1.56] 0.16[0.02; 1.56]ORIENT-11, 202010%397NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:40 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 874